Herpes zoster vaccination in systemic lupus erythematosus: the current status
Among the inflammatory rheumatic diseases, SLE is associated with the highest risk of herpes zoster reactivation relative to age. The reported incidence of herpes zoster infection in SLE ranges from 6.4 to 91.4/1000 patient-years, with main risk factors being major organ disease, immunosuppressive a...
Main Author: | Chi Chiu Mok |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2019-01-01
|
Series: | Human Vaccines & Immunotherapeutics |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/21645515.2018.1514228 |
Similar Items
-
Herpes zoster in patients with systemic lupus erythematosus
by: Maria Bibiana Leroux
Published: (2016-10-01) -
Reactivation of Herpes Zoster Keratitis Following Shingrix Vaccine
by: Tracy J. Lu, et al.
Published: (2022-02-01) -
Studies with herpes zoster vaccines in immune compromised patients
by: Myron J. Levin, et al.
Published: (2017-12-01) -
Herpes zoster in lupus nephritis: experience on 292 patients followed up for 15 years
by: Francesco Reggiani, et al.
Published: (2023-11-01) -
Prevention of Herpes Zoster: A Focus on the Effectiveness and Safety of Herpes Zoster Vaccines
by: Yasmin Marra, et al.
Published: (2022-11-01)